Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
175 hedge funds and large institutions have $1.21B invested in Eagle Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 76 increasing their positions, 42 reducing their positions, and 5 closing their positions.
620% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 5
162% more call options, than puts
Call options by funds: $12.4M | Put options by funds: $4.72M
81% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 42
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
19% more funds holding
Funds holding: 147 → 175 (+28)
11% less capital invested
Capital invested by funds: $1.36B → $1.21B (-$152M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$150M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$67.4M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$23.5M |
| 4 |
Lazard Asset Management
New York
|
+$20.8M |
| 5 |
Morgan Stanley
New York
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$55.7M |
| 2 |
RIM
Ranger Investment Management
Dallas,
Texas
|
-$10.4M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$8.53M |
| 4 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$6.66M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$6.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
D.E. Shaw & Co
New York
| – | -$650K | -7,843 | Closed |
|
|
TRCT
177
Tower Research Capital (TRC)
New York
| – | -$32K | -391 | Closed |
|
|
HMS
178
Hanseatic Management Services
Albuquerque,
New Mexico
| – | -$1K | -8 | Closed |
|
|
QT
179
Quantbot Technologies
New York
| – | +$818 | +10 | New |
|
EGRX Hedge Fund Activity: Q2 2017 in Review
175 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q2 2017, worth a combined $1.21B — down 11% from $1.36B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new EGRX positions and 5 closed out — a net gain of 31 holders — while 76 added to existing stakes and 42 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $150M. The largest seller was OrbiMed, exiting entirely with an estimated $55.7M sold.
- 175 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q2 2017, up from 147 in Q1 2017.
- Funds reported $1.21B of Eagle Pharmaceuticals, Inc. stock for Q2 2017, down 11% quarter-over-quarter.
- 36 funds opened new Eagle Pharmaceuticals, Inc. positions in Q2 2017 and 5 closed out, a net change of +31 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q2 2017 was Janus Henderson Group, an estimated $150M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q2 2017 was OrbiMed, an estimated $55.7M sold.
Based on aggregated 13F filings for Q2 2017.